Home › Funds › Eaton Vance › Eaton Vance Worldwide Health Sciences Fund
Fund family: Eaton Vance · Filed by Eaton Vance Growth Trust (CIK 102816) · SEC series S000005202
Share classes and tickers: ECHSX (C000014193), EIHSX (C000081646), ERHSX (C000014194), ETHSX (C000014191)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 554 with, 16 against, 0 abstentions (not counted as with management); 9 items carried no recommendation. Shareholder proposals: 13 FOR, 11 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Eaton Vance’s manager page (83,378 ballot items across 42 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Eaton Vance | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 95.7% | 511 | 86.3% | 60,657 |
| Backed environmental and social shareholder proposals at US companies | n/a | 6 | 22.5% | 946 |
Each ballot item this fund voted is set against the votes of the other Eaton Vance funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Eaton Vance funds on 1 item (0.3% of the 328 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Eaton Vance funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. | 2026-05-20 | An advisory vote to approve named executive officer compensation. | For | AGAINST — 5 of 7 Eaton Vance funds | For | Not approved, 31.8% support |
Download all 1 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 61.6% of this fund’s 570 such votes could be given a sector; the other 219 (38.4%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 313 | 15 | 4.8% |
| Industrials | 38 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 347 | 0 |
| Compensation | 59 | 1 |
| Corporate Governance | 51 | 9 |
| Capital Structure | 44 | 0 |
| Audit-related | 43 | 0 |
| Say-on-Pay | 28 | 0 |
| Other Social Issues | 4 | 3 |
| Environment or Climate | 3 | 3 |
| Shareholder Rights and Defenses | 2 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $134M | 10 | 2 |
| AbbVie Inc. | May 8, 2026 | $70M | 8 | 1 |
| Johnson & Johnson | April 23, 2026 | $61M | 15 | 1 |
| UnitedHealth Group Incorporated | June 1, 2026 | $45M | 12 | 1 |
| Merck & Co., Inc. | May 26, 2026 | $44M | 18 | 3 |
| Bristol-Myers Squibb Company | May 5, 2026 | $35M | 15 | 1 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $33M | 13 | 0 |
| Gilead Sciences, Inc. | April 30, 2026 | $32M | 15 | 3 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | For | Against |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 5, 2026 | Bristol-Myers Squibb Company | Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
| May 20, 2026 | Zoetis Inc. | Shareholder proposal to permit shareholder action by written consent. Shareholder proposal | For | Against |
581 ballot items at 43 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Eaton Vance Worldwide Health Sciences Fund (ECHSX) voted at 43 shareholder meetings of 40 companies, on 581 ballot items in all. Where management made a recommendation, the fund followed it on 97.2% of the items and voted against it 16 times. Its most frequent area of disagreement was corporate governance (9 of its votes against management). It voted on 24 shareholder proposals. It voted FOR the board's own proposals more often than Eaton Vance's funds as a whole (95.7% against 86.3%). It voted differently from most Eaton Vance funds on 1 item.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Eaton Vance’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.